Development of Engager T cells for immunotherapy of lung cancer
| Project/Area Number |
15K09218
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
IWAHORI KOTA 大阪大学, 医学系研究科, 特任講師(常勤) (80566448)
|
|---|
| Project Period (FY) |
2015-10-21 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | がん免疫療法 |
|---|
| Outline of Final Research Achievements |
We generated T cells expressing a secretable bispecific T-cell engager (Engager-T cells) for cancer immunotherapy. For the development of Engager T cells against lung cancer, we evaluated detailed immunological aspects in clinical specimens from non-small cell lung cancer (NSCLC) patients. We analyzed the immune profiles and T cell cytotoxicity of lung tumor tissue from NSCLC patients. By using bispecific T-cell engager (BiTE) to assess the cytotoxicity of T cells, we found that the cytotoxicity of tumor-infiltrated T cells correlated with immune profiles and smoking status of NSCLC patients. These results imply predictive biomarkers for the efficacy of Engager-T cells.
|
Report
(4 results)
Research Products
(1 results)
